乳腺癌新辅助化疗疗效及其与生物标志物检测水平变化的相关性

目的:探讨乳腺癌新辅助化疗疗效及其与生物标志物检测水平变化的相关性。方法:通过对乳腺癌新辅助化疗患者疗效的评估以及空心针穿刺标本和手术标本的免疫组织化学染色比较，分析新辅助化疗疗效与生物标志物改变情况，以及二者的关系、影响因素。结果:在76例新辅助化疗的患者中，达到病理完全缓解（pCR）的患者有14例(18.4%)，临床有效率达75.00%。对新辅助化疗疗效的相关因素分析，发现雌激素受体（ER）、孕激素受体（PR）状态与疗效相关（P均<0.05）。进一步对14例达到pCR患者的生物标志物进行分析，ER阴性的患者有10例(71.4%)、PR阴性的患者有9例(64.3%)。对比生物标志物，发现新辅助化疗患者Ki-67改变差异有统计学意义（P＜0.05），而ER、PR、p53改变情况差异无统计学意义（P均＞0.05）。结论:新辅助化疗具有较高的临床缓解率，新辅助化疗疗效与ER、PR状态有关，ER、PR表达较弱者相对较容易达到pCR，并且新辅助化疗后患者生物标志物只有Ki-67改变。

Correlation analysis of efficacy and biomarker level changes after neoadjuvant chemotherapy in breast cancer

Objective:To study the effect of neoadjuvant chemotherapy in breast cancer and its relationship with the change of biomarkers.Methods:By evaluating the curative effect of neoadjuvant chemotherapy for breast cancer and comparing the immunohistochemical staining of hollow needle puncture specimen with operation specimen,the effect of neoadjuvant chemotherapy and the change of biomarkers were analyzed,and the relationship between them was analyzed.Influencing factors were analysed.Results:In 76 patients with neoadjuvant chemotherapy,14(18.4%) had achieved complete pathological(pCR),and the clinical effective rate was 75.00%(CR+PR).The related factors of the therapeutic effect of neoadjuvant chemotherapy were analyzed.It was found that the state of ER,PR was correlated with the curative effect(P＜0.05).Further analysis of biomarkers in 14 patients with pCR showed that 10 cases(71.4%) were ER negative and 9 cases(64.3%) were negative for PR.Compared with the biomarkers,the changes of Ki-67 in neoadjuvant chemotherapy patients were statistically significant(P＜0.05),but the changes of ER,PR,p53 were not significant(P＞0.05).Conclusion:Neoadjuvant chemotherapy has a higher clinical remission rate.The neo-adjuvant curative effect is related to the state of ER,PR.The expression of ER,PR is relatively easy to reach pCR,in patients with neo-adjuvant chemotherapy.Only Ki-67 changes in the biomarkers after neoadjuvant chemotherapy.